Form 4: Heron Therapeutics EVP Converts RSUs to Common Stock

Heron Therapeutics' EVP, Chief Development Officer, William P. Forbes, converted 3,875 restricted stock units into common stock.

Summary

• William P. Forbes, Executive Vice President and Chief Development Officer of Heron Therapeutics, Inc., reported a change in beneficial ownership.
• On January 19, 2026, Forbes acquired 3,875 shares of common stock.
• This acquisition resulted from the vesting and conversion of 3,875 Restricted Stock Units (RSUs).
• Following this transaction, Forbes directly beneficially owns 170,078 shares of common stock.
• Forbes also directly beneficially owns 30,994 Restricted Stock Units.
• The Restricted Stock Units vest in 16 equal quarterly installments, with vesting commencing one quarter after the grant date of January 19, 2024.

Sentiment

Score: 6

Explanation: This filing details a routine executive compensation event (vesting of Restricted Stock Units). While generally neutral, the conversion to common stock slightly increases the executive's direct equity stake, which can be viewed as a minor positive for aligning interests with shareholders.

Positives

• Increased direct common stock ownership by a key executive, which aligns management's interests more closely with those of shareholders.

Future Outlook

No specific forward-looking statements or guidance are provided in this filing, as it pertains to a past executive compensation event.

Industry Context

This transaction represents a routine executive compensation event, specifically the vesting and conversion of Restricted Stock Units, which is a common practice across various industries to incentivize and retain key management personnel. It does not reflect broader industry trends or competitive dynamics.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a widely adopted practice across publicly traded companies, including those in the biotechnology and pharmaceutical sectors, aligning executive incentives with long-term shareholder value.
• The vesting schedule of 16 equal quarterly installments is a standard approach to phased equity grants, comparable to practices observed at companies like Amgen Inc. or Gilead Sciences, Inc., which also utilize multi-year vesting periods for executive equity awards.

Related Party Transactions

• The conversion of Restricted Stock Units (RSUs) into common stock for an executive is a standard form of related-party compensation, executed under the terms of an existing equity incentive plan.

Stakeholder Impact

• Shareholders: A minor increase in the number of outstanding shares due to the RSU conversion, which is a common form of dilution from equity compensation. However, it also signifies increased alignment of a key executive's financial interests with those of shareholders.
• Employees: No direct impact on general employees is indicated by this specific filing.

Next Steps

• The remaining 30,994 Restricted Stock Units held by William P. Forbes will continue to vest in quarterly installments according to the established schedule.

Key Dates

Recommendation

This Form 4 filing details a routine vesting and conversion of Restricted Stock Units by a key executive. While it increases the executive's direct equity stake, aligning interests with shareholders, it does not present new operational or financial information that would warrant a change in investment recommendation based solely on this report. It is a standard compensation event and does not alter the fundamental investment thesis for the company.

Keywords

Heron Therapeutics, HRTX, Form 4, insider transaction, restricted stock units, RSU conversion, executive compensation, beneficial ownership